Leading the way to new and better cancer treatments

About Polaris

Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies.
Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others.

Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP Production Facilities in Northern California and China.

Clinical Trials

Pegargiminase is in clinical development for numerous oncology indications.
Mesothelioma
Phase 3
Soft Tissue Sarcoma
Phase 2
Glioblastoma
Phase 1
Hepatic Cell Carcinoma
Phase 2/3
Acute Myeloid Leukemia
Phase 1

Development and Manufacturing Capabilities

Company News

English

Polris Group received approval from the Listing Review Committee of Taiwan Stock Exchange for Primary Listing

The Taiwan Stock Exchange Corporation held its 755th Listing Review Committee meeting on March 4, 2022 and approved the application of Polaris Group for primary …

Read More
English

Polaris Pharmaceuticals steps into mRNA technology and actively integrates macromolecular pharmaceutical technology

Multinational biotech company Polaris signed an industry sponsored research agreement with UC Irvine’s (UCI) Vaccine Research and Development Center to fund “Fluvid,” a universal messenger RNA (mRNA) influenza and …

Read More
English

Polaris Pharmaceuticals applies for the first listing

Polaris Group Polaris Pharmaceuticals – KY (6550TW) rush to the stock exchange to apply for the first listing of shares before the end of 2021! …

Read More
English

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a Universal Influenza and Coronavirus Vaccine.

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine.

Read More

Contact Us

Thank you for visiting. Please fill out the form with your specific details and submit it to us. We will contact you shortly. Thank you. *required.




    Enter Captcha Here :

    Scroll to Top